Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03451890 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730 in Healthy Participants
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT03451890 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 32 participants.
The verdict
NCT03451890, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study will be conducted to evaluate the safety, tolerability, and pharmacokinetics of single ascending oral doses of E2730 in healthy adult participants.
Interventions
- DRUG Placebo
- DRUG E2730
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-02-09 |
| Est. Completion | 2018-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03451890
The ClinicalTrials.gov registry entry for NCT03451890 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03451890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03451890 about?
NCT03451890 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730 in Healthy Participants". This study will be conducted to evaluate the safety, tolerability, and pharmacokinetics of single ascending oral doses of E2730 in healthy adult participants.
What is the current status of trial NCT03451890?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2018-02-09. Estimated completion is 2018-09-26.
What interventions are being tested in trial NCT03451890?
The interventions under investigation include: Placebo (DRUG), E2730 (DRUG).
Who is sponsoring clinical trial NCT03451890?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.